

Amendment To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A product capable of having anti-inflammatory properties,
wherein said product is obtainable from starfish,
wherein said product is glycoprotein,
wherein said glycoprotein has a molecular weight of about 1,100 kDa as measured by 3% polyacrylamide gel electrophoresis,
wherein the glycoprotein exhibits at least one characteristic selected from the group consisting of:

- a) sensitivity to the action of chondroitinase ABC I,
- b) sensitivity to the action of N-glycanase,
- c) resistance to the action of chondroitinases ACI and B,
- d) resistance to the action of proteinase K,
- e) resistance to the action of papain, and
- f) sensitivity to the action of neuraminidase;

and the product has:

a characteristic nuclear magnetic resonance proton spectrum at 500 MHz as shown in FIG. 1 of the drawings; and

a characteristic Fourier transform infra-red spectrum as shown in FIG. 2 of the drawings.

2. (Previously presented) A product according to claim 1 wherein said product is obtainable from the mucus secretions of the starfish.

3. (Previously presented) A product according to claim 1 wherein the starfish is *Marthasterias glacialis*.

Claims 4-6 (Canceled)

7. (Original) A product according to claim 1, said product not having significant anticoagulant properties.

8. (Previously presented) A method for the preparation of a product capable of having anti-inflammatory properties, wherein said product is obtainable from starfish, wherein said product is glycoprotein, wherein said glycoprotein has a molecular weight of about 1,100 kDa as measured by 3% polyacrylamide gel electrophoresis, wherein the glycoprotein exhibits at least one characteristic selected from the group consisting of:

- a) sensitivity to the action of chondroitinase ABC I,
- b) sensitivity to the action of N-glycanase,
- c) resistance to the action of chondroitinases ACI and B,
- d) resistance to the action of proteinase K,
- e) resistance to the action of papain, and
- f) sensitivity to the action of neuraminidase,

said method comprising:

- a) collecting mucus from *Marthasterias glacialis*,
- b) removing particulate material by centrifugation,
- c) subjecting the supernatant to column chromatography,
- d) eluting the product from the chromatography column of (c), and
- e) optionally dialysing said eluted product against distilled water.

9-10. (Canceled)

11. (Original) A pharmaceutical comprising the product of claim 1.

Claims 12-19 (Canceled)

20. (Currently amended) A composition comprising a glycoprotein obtainable from the mucus secretions of *Marthasterias glacialis* which exhibits a molecular weight of about 1,100 kDa as measured by 3 % polyacrylamide gel electrophoresis, and is sensitive to the action of chondroitinase ABC I, sensitive to the action of N-glycanase, sensitive to the action of neuraminidase, resistant to the action of chondroitinases ACI and B, resistant to the action of proteinase K, and resistant to the action of papain and which has a characteristic nuclear magnetic resonance proton spectrum at 500 MHz as shown in FIG. 1 of the drawings; and a characteristic Fourier transform infra-red spectrum as shown in FIG. 2 of the drawings.